We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+6.27%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.02B
AUM Growth
-$45.6M
Cap. Flow
-$64.3M
Cap. Flow %
-6.32%
Top 10 Hldgs %
45.69%
Holding
126
New
39
Increased
20
Reduced
28
Closed
30

Top Buys

Rank Stock Value
1
BTAI icon
BioXcel Therapeutics
BTAI
+$12.6M
2
JNJ icon
Johnson & Johnson
JNJ
+$11.8M
3
GNRC icon
Generac Holdings
GNRC
+$11M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$10.6M
5
LLY icon
Eli Lilly
LLY
+$10.2M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$41.2M
2
NVO
Novo Nordisk
NVO
+$26.2M
3
NICE icon
Nice
NICE
+$14.2M
4
FVRR icon
Fiverr
FVRR
+$11.8M
5
QTTB icon
Q32 Bio
QTTB
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 70.42%
2 Technology 5.67%
3 Consumer Discretionary 2.57%
4 Industrials 2.19%
5 Communication Services 1.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RETA
51
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.76M 0.57%
59,139
-22,910
-28% -$2.86M
ARNA
52
DELISTED
Arena Pharmaceuticals Inc
ARNA
$5.61M 0.55%
+75,000
New +$5M
ARYBU
53
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
$5.49M 0.54%
499,000
+199,000
+66% +$2.26M
CLDX icon
54
Celldex Therapeutics
CLDX
$2.99B
$5.49M 0.54%
+370,000
New +$4.33M
MRTX
55
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$5.48M 0.54%
33,000
-39,000
-54% -$5.34M
SIOX
56
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$5.33M 0.52%
1,152,998
-1,705,000
-60% -$5.63M
RCKT icon
57
Rocket Pharmaceuticals
RCKT
$340M
$5.21M 0.51%
228,016
-112,000
-33% -$2.76M
LRMR icon
58
Larimar Therapeutics
LRMR
$397M
$5.19M 0.51%
342,064
-54,723
-14% -$693K
KYMR icon
59
Kymera Therapeutics
KYMR
$8.51B
$5.17M 0.51%
+160,000
New +$4.88M
INZY
60
DELISTED
Inozyme Pharma
INZY
$5.16M 0.51%
+196,411
New +$4.88M
ASND icon
61
Ascendis Pharma A/S
ASND
$16B
$5.03M 0.49%
32,599
-1,774
-5% -$255K
QURE icon
62
uniQure
QURE
$3.03B
$4.64M 0.46%
126,000
+16,000
+15% +$655K
NAUT icon
63
Nautilus Biotechnolgy
NAUT
$124M
$4.29M 0.42%
+400,000
New +$4.27M
GRTX
64
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$4.24M 0.42%
469,245
– –
TECX
65
Tectonic Therapeutic
TECX
$529M
$4.24M 0.42%
+27,125
New +$5.46M
KNSA icon
66
Kiniksa Pharmaceuticals
KNSA
$5.8B
$3.98M 0.39%
+259,990
New +$4.88M
ZYME icon
67
Zymeworks
ZYME
$1.61B
$3.73M 0.37%
80,000
-36,310
-31% -$1.25M
DRNA
68
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$3.6M 0.35%
+199,980
New +$4.14M
PASG icon
69
Passage Bio
PASG
$14.4M
$3.49M 0.34%
13,302
-3,920
-23% -$1.35M
PRGO icon
70
Perrigo
PRGO
$1.4B
$3.29M 0.32%
71,559
+21,559
+43% +$1.13M
ALT icon
71
Altimmune
ALT
$552M
$3.21M 0.32%
+243,000
New +$4.86M
ARVN icon
72
Arvinas
ARVN
$518M
$3.19M 0.31%
+135,000
New +$3.91M
CNCE
73
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$3.04M 0.3%
310,000
-390,710
-56% -$3.85M
KALV
74
DELISTED
KalVista Pharmaceuticals
KALV
$3.02M 0.3%
240,140
– –
ARGX icon
75
argenx
ARGX
$53.4B
$2.69M 0.26%
10,265
– –
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2020 Portfolio in Review

As of Q3 2020, Sphera Funds Management held 126 positions worth $1.02B, down 4.3% from $1.06B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Sphera Funds Management withdrew a net $64.3M in Q3 2020, closing 30 positions and reducing 28 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $41.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 64% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Sphera Funds Management opened a new position in BioXcel Therapeutics worth $11.7M.

  • Sphera Funds Management's largest Q3 2020 buy was BioXcel Therapeutics: 16,831 shares worth $11.7M.
  • Sphera Funds Management added most to Johnson & Johnson in Q3 2020, an estimated $11.8M increase.
  • Sphera Funds Management's biggest Q3 2020 reduction was Nice, cutting an estimated $14.2M.
  • Sphera Funds Management fully exited Bristol-Myers Squibb in Q3 2020, selling an estimated $41.2M.
  • Sphera Funds Management's ten largest holdings make up 46% of its $1.02B portfolio in Q3 2020.
  • Sphera Funds Management opened 39 new positions and closed 30 in Q3 2020.
  • Sphera Funds Management's portfolio value fell 4.3% quarter-over-quarter to $1.02B.

Based on Sphera Funds Management's 13F filing for Q3 2020, filed 12 Nov 2020.